The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin
- 1 July 1988
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 22 (1) , 11-16
- https://doi.org/10.1007/bf00254173
Abstract
Since the reactivity of carboplatin depends on the rate of removal of the 1,1-cyclobutanedicarboxylate ligand, the time course of this dissociation has been determined in various tissue and body fluids using 14C-labelled carboplatin (cis-diammine[1,1-cyclobutane-1-14C-dicarboxylate]platinum II). Mice received 14C-carboplatin (80 mg/kg; 1.1 mCi/kg, i.v.), and tissue was removed at times ranging from 5 min to 5 days posttreatment. Following solubilization, tissue aliquots were analyzed for platinum and 14C contents. Carboplatin remained intact for up to 2 h posttreatment, since the ratio of 14C:Pt in tissues (nmol/g) was unity. Thereafter, the 14C ligand was released from the molecule and preferentially removed from tissues, indicated by decreasing 14C:Pt ratios. The elimination half-lifes for Pt varied between tissues (40–156 h). In contrast, the corresponding half-lifes for the 14C species were similar in most types of tissue (18–35 h), although those in the liver and spleen were excetpional (210 and 90 h, respectively). At 5 days a maximum of 4%–24% of the total Pt in tissue might exist as intact drug. Thus, the metabolic handling of carboplatin varies according to the tissue, since the elimination of the 14C cyclobutane dicarboxylate species from most tissue was similar and Pt elimination was slower and tissue-dependent.This publication has 15 references indexed in Scilit:
- Ovarian trials at the Royal MarsdenCancer Treatment Reviews, 1985
- Cis-diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary reportCancer Treatment Reviews, 1985
- Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancerCancer Treatment Reviews, 1985
- Results of NCI-sponsored phase I trials with carboplatinCancer Treatment Reviews, 1985
- In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma cameraCancer Chemotherapy and Pharmacology, 1985
- A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II)Cancer Chemotherapy and Pharmacology, 1983
- Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IICancer Chemotherapy and Pharmacology, 1982
- The fate of lysergic acid di[14C]ethylamide ([14C]LSD) in the rat, guinea pig and rhesus monkey and of [14C]iso-LSD in ratBiochemical Pharmacology, 1979
- Cisplatin (cis-diamminedichloroplatinum II)Cancer Treatment Reviews, 1979
- Distribution of cis-platin in bloodChemico-Biological Interactions, 1978